Neuphoria Therapeutics Inc.
NEUP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001191070
No open-market purchases or sales by Neuphoria Therapeutics Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $8.71M in total; no superinvestor holds it.
Holders of 5% or more of NEUP
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Neuphoria Therapeutics Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 13D/A | 16.30%875.3K shares | 0.00 ppfrom 16.30% | Oct 23, 20256 filings | Dec 29, 2025 | SEC |
| Shay Capital LLC | 13G | 7.30%171.6K shares | New | Oct 31, 20251 filing | Oct 31, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
13 Schedule 13D and 13G filings on Neuphoria Therapeutics Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 28, 202610:31 AM ET | Coastlands Capital LPand 4 others | 13G/A | 4.23%228.6K shares | −0.87 ppfrom 5.10%Below 5% | Jul 23, 2026 | SEC |
| Feb 6, 20264:29 PM ET | Baselake Partners, LPand 2 others | 13G/A | 4.10%222.2K shares | −5.30 ppfrom 9.40%Below 5% | Dec 31, 2025 | SEC |
| Dec 29, 20254:33 PM ET | Lynx1 Capital Management LPand 1 other | 13D/A | 16.30%875.3K shares | 0.00 ppfrom 16.30% | Dec 26, 2025 | SEC |
| Dec 2, 20258:20 AM ET | Lynx1 Capital Management LPand 1 other | 13D/A | 16.30%875.3K shares | 0.00 ppfrom 16.30% | Dec 2, 2025 | SEC |
| Nov 28, 20259:09 AM ET | Lynx1 Capital Management LPand 1 other | 13D/A | 16.30%875.3K shares | 0.00 ppfrom 16.30% | Nov 28, 2025 | SEC |
| Nov 18, 20258:25 AM ET | Lynx1 Capital Management LPand 1 other | 13D/A | 16.30%875.3K shares | −10.20 ppfrom 26.50% | Nov 18, 2025 | SEC |
| Nov 10, 20252:33 PM ET | Lynx1 Capital Management LPand 1 other | 13D/A | 26.50%875.3K shares | −10.60 ppfrom 37.10% | Nov 9, 2025 | SEC |
| Nov 5, 202510:31 AM ET | Coastlands Capital LPand 4 others | 13G | 5.10%120.0K shares | New | Nov 5, 2025 | SEC |
| Oct 31, 20254:31 PM ET | Baselake Partners, LPand 2 others | 13G | 9.40%222.2K shares | New | Oct 27, 2025 | SEC |
| Oct 31, 20254:00 PM ET | Shay Capital LLCand 1 other | 13G | 7.30%171.6K shares | New | Oct 24, 2025 | SEC |
| Oct 23, 20257:52 PM ET | Lynx1 Capital Management LPand 1 other | 13D | 37.10%875.3K shares | New | Oct 21, 2025 | SEC |
| Feb 14, 20255:06 PM ET | Armistice Capital, LLCand 1 other | 13G/A | 4.99%1.03M shares | –Below 5% | Dec 31, 2024 | SEC |
| Jan 28, 20254:30 PM ET | Apeiron Investment Group Ltd.and 4 others | 13D/A | 4.50%72.6K shares | –Below 5% | Jan 24, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Neuphoria Therapeutics Inc. shares.
No Form 144 notices for Neuphoria Therapeutics Inc. are on file.